Similarly, the majority of meta-analysis pooling results from clinical trials suggest that there is not a significant risk of all-cause infection, upper respiratory tract infections, or pneumonia associated with using a DPP4 inhibitor. This evidence concerns the gene DPP4 and susceptibility to pneumonia measurement.